SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-428560"
 

Sökning: id:"swepub:oai:DiVA.org:uu-428560" > Radionuclide therap...

Radionuclide therapy using ABD-fused ADAPT scaffold protein : Proof of Principle

Garousi, Javad (författare)
Uppsala universitet,Medicinsk strålningsvetenskap,Vladimir Tolmachev,Uppsala Univ, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.
von Witting, Emma (författare)
KTH,Proteinteknologi
Borin, Jesper (författare)
KTH,Proteinteknologi
visa fler...
Vorobyeva, Anzhelika (författare)
Uppsala universitet,Medicinsk strålningsvetenskap,Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Research Tomsk Polytechnic University, Tomsk, Russia,Vladimir Tolmachev,Uppsala Univ, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.;Res Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk, Russia.
Altai, Mohamed (författare)
Uppsala universitet,Medicinsk strålningsvetenskap,Vladimir Tolmachev,Uppsala Univ, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.
Vorontsova, Olga (författare)
Uppsala universitet,Medicinsk strålningsvetenskap,Vladimir Tolmachev,Uppsala Univ, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.
Konijnenberg, Mark W. (författare)
Erasmus MC, Dept Radiol & Nucl Med, Rotterdam, Netherlands.
Oroujeni, Maryam, PhD, 1982- (författare)
Uppsala universitet,Medicinsk strålningsvetenskap,Vladimir Tolmachev,Uppsala Univ, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.
Orlova, Anna, 1960- (författare)
Uppsala universitet,Theranostics,Science for Life Laboratory, SciLifeLab,Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Research Tomsk Polytechnic University, Tomsk, Russia,Anna Orlova,Res Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk, Russia.;Uppsala Univ, Dept Med Chem, Uppsala, Sweden.;Uppsala Univ, Sci Life Lab, Uppsala, Sweden.
Tolmachev, Vladimir (författare)
Uppsala universitet,Medicinsk strålningsvetenskap,Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Research Tomsk Polytechnic University, Tomsk, Russia,Vladimir Tolmachev,Uppsala Univ, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.;Res Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Res Ctr Oncotheranost, Tomsk, Russia.
Hober, Sophia, Professor, 1965- (författare)
KTH,Proteinteknologi
visa färre...
 (creator_code:org_t)
Elsevier, 2021
2021
Engelska.
Ingår i: Biomaterials. - : Elsevier. - 0142-9612 .- 1878-5905. ; 266
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Molecular recognition in targeted therapeutics is typically based on immunoglobulins. Development of engineered scaffold proteins (ESPs) has provided additional opportunities for the development of targeted therapies. ESPs offer inexpensive production in prokaryotic hosts, high stability and convenient approaches to modify their biodistribution. In this study, we demonstrated successful modification of the biodistribution of an ESP known as ADAPT (Albumin-binding domain Derived Affinity ProTein). ADAPTs are selected from a library based on the scaffold of ABD (Albumin Binding Domain) of protein G. A particular ADAPT, the ADAPT6, binds to human epidermal growth factor receptor type 2 (HER2) with high affinity. Preclinical and early clinical studies have demonstrated that radiolabeled ADAPT6 can image HER2-expression in tumors with high contrast. However, its rapid glomerular filtration and high renal reabsorption have prevented its use in radionuclide therapy. To modify the biodistribution, ADAPT6 was genetically fused to an ABD. The non-covalent binding to the host's albumin resulted in a 14-fold reduction of renal uptake and appreciable increase of tumor uptake for the best variant, 177Lu-DOTA-ADAPT6-ABD035. Experimental therapy in mice bearing HER2-expressing xenografts demonstrated more than two-fold increase of median survival even after a single injection of 18 MBq 177Lu-DOTA-ADAPT6-ABD035. Thus, a fusion with ABD and optimization of the molecular design provides ADAPT derivatives with attractive targeting properties for radionuclide therapy.

Ämnesord

TEKNIK OCH TEKNOLOGIER  -- Industriell bioteknik -- Medicinsk bioteknik (hsv//swe)
ENGINEERING AND TECHNOLOGY  -- Industrial Biotechnology -- Medical Biotechnology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)

Nyckelord

177Lu
ABD (Albumin binding domain)
ADAPT (Albumin-binding domain derived affinity ProTein)
Biodistribution modification
HER2
Radionuclide therapy

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy